Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) announced that CEO Michael Halstead will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York City. The fireside chat will be webcast live on Sept. 16 at 8:30 a.m. EDT, with a replay available on the Events & Presentations page of Helus Pharma's investor relations website.
The conference appearance is significant as it provides Helus Pharma with a platform to engage with institutional investors, analysts, and industry peers at a prestigious healthcare investment event. Morgan Stanley's Global Healthcare Conference is widely attended by key decision-makers in the healthcare sector, and participation can enhance a company's visibility and credibility. For Helus Pharma, this exposure may help attract investment and partnerships as it advances its pipeline of novel serotonergic agonists (NSAs) for mental health conditions.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary NSAs: synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity. The company's proprietary NSAs are intended to address the large unmet need for people who suffer from depression, anxiety, and other mental health conditions.
With class-leading data, Helus Pharma aims to improve the treatment landscape through the introduction of NSAs that aim to provide durable improvements in mental health. The company is currently developing HLP003, a proprietary NSA, in Phase 3 clinical development for the adjunctive treatment of major depressive disorder. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, which is designed to expedite the development and review of drugs that may demonstrate substantial improvement over available therapies. Additionally, Helus Pharma is developing HLP004, also a proprietary NSA, in Phase 2 for generalized anxiety disorder. The company also has an extensive research portfolio of investigational NSAs.
Mental health disorders such as major depressive disorder and generalized anxiety disorder affect millions of people worldwide, and existing treatments often fail to provide adequate relief. The development of new therapies with novel mechanisms of action is critical to addressing this unmet need. Helus Pharma's focus on NSAs represents a promising approach that could offer new options for patients who do not respond to conventional treatments.
The company operates in Canada, the United States, the United Kingdom, and Ireland. For company updates and to learn more about Helus Pharma, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram. Helus Pharma is a trademark of Cybin Corp.
Investors and other interested parties can find the latest news and updates relating to HELP in the company's newsroom at https://ibn.fm/HELP. To view the full press release, visit https://ibn.fm/r0jfC.
BioMedWire (BMW) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed), and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions. For more information, please visit https://www.BioMedWire.com. Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer.
